The estimated Net Worth of Ivana Magovcevic Liebisch is at least $134 mil dollars as of 16 November 2016. Ivana Liebisch owns over 3,000 units of Aeglea BioTherapeutics Inc stock worth over $36,030 and over the last 10 years he sold AGLE stock worth over $0. In addition, he makes $97,809 as Independent Director at Aeglea BioTherapeutics Inc.
Sign up
Ivana Liebisch AGLE stock SEC Form 4 insiders trading
Ivana has made over 1 trades of the Aeglea BioTherapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of AGLE stock worth $28,890 on 16 November 2016.
The largest trade he's ever made was buying 3,000 units of Aeglea BioTherapeutics Inc stock on 16 November 2016 worth over $28,890. On average, Ivana trades about 167 units every 0 days since 2014. As of 16 November 2016 he still owns at least 3,000 units of Aeglea BioTherapeutics Inc stock.
You can see the complete history of Ivana Liebisch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ivana Magovcevic-Liebisch biography
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. serves as Independent Director of the Company. Dr. Magovcevic-Liebisch has served as Executive Vice President, Chief Business Officer for Ipsen since March 2018. From May 2017 through March 2018, Dr. Magovcevic-Liebisch served as Executive Vice President, Chief Strategy and Corporate Development Officer for Axcella Health Inc. From April 2013 through May 2017, Dr. Magovcevic-Liebisch served as Senior Vice President, Head of Global Business Development for Teva Pharmaceutical Industries Ltd. Prior to joining Teva, Dr. Magovcevic-Liebisch held several senior positions within Dyax Corp., or Dyax, from April 2001 through March 2013, most recently serving as Executive Vice President and Chief Operating Officer. Dr. Magovcevic-Liebisch currently serves on the board of directors of Applied Genetic Technologies Corporation, a biotechnology company, as well as several other private companies. Dr. Magovcevic-Liebisch received her J.D. from Suffolk University Law School and her Ph.D. in genetics from Harvard University. Magovcevic-Liebisch’s extensive experience in biopharmaceutical business development and operations qualify her to serve as a member of our board of directors.
What is the salary of Ivana Liebisch?
As the Independent Director of Aeglea BioTherapeutics Inc, the total compensation of Ivana Liebisch at Aeglea BioTherapeutics Inc is $97,809. There are 8 executives at Aeglea BioTherapeutics Inc getting paid more, with Anthony Quinn having the highest compensation of $2,482,780.
How old is Ivana Liebisch?
Ivana Liebisch is 53, he's been the Independent Director of Aeglea BioTherapeutics Inc since 2018. There are 7 older and 8 younger executives at Aeglea BioTherapeutics Inc. The oldest executive at Aeglea BioTherapeutics Inc is V. Bryan Lawlis, 68, who is the Independent Director.
What's Ivana Liebisch's mailing address?
Ivana's mailing address filed with the SEC is C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN, TX, 78746.
Insiders trading at Aeglea BioTherapeutics Inc
Over the last 9 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag... y Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.
What does Aeglea BioTherapeutics Inc do?
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
What does Aeglea BioTherapeutics Inc's logo look like?
Complete history of Ivana Liebisch stock trades at Aeglea BioTherapeutics Inc y Applied Genetic Technologies Corp
Aeglea BioTherapeutics Inc executives and stock owners
Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include:
-
Anthony Quinn,
President and Chief Executive Officer, Director -
Leslie Sloan,
Chief Operating Officer -
Charles York,
Chief Financial Officer, Vice President -
Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP,
Pres, CEO & Director -
Dr. Leslie S. Sloan Ph.D.,
Chief Operating Officer -
Russell Cox,
Independent Chairman of the board -
Sandesh Mahatme,
Independent Director -
Suzanne Bruhn,
Independent Director -
Ivana Magovcevic-Liebisch,
Independent Director -
V. Bryan Lawlis,
Independent Director -
Armen Shanafelt,
Independent Director -
Joey Perrone,
Director, Finance & Investor Relations -
Ravi Rao,
Chief Medical Officer -
Michael Hanley,
Chief Commercial Officer -
Michael C. Hanley M.B.A.,
Chief Commercial Officer -
Eugene Sackett,
VP of HR -
Kelly Boothe Ph.D.,
Sr. Director of Corp. Communications -
James Paul Kastenmayer J.D., Ph.D.,
Gen. Counsel -
Cortney Caudill M.B.A.,
Sr. VP of Technical Operations -
Steven Weber,
VP, Principal Accounting Officer & Corp. Controller -
Jonathan D. Alspaugh M.B.A.,
Chief Financial Officer -
Aaron Schuchart,
Chief Business Officer -
Joseph E Tyler,
VP, Manufacturing -
Scott W Rowlinson,
VP, Research -
David George Lowe,
CEO and President -
Henry Hebel,
VP, Product Development -
Advisors Llc Orbi Med Capit...,
-
George Georgiou,
Director -
Lilly & Co Eli,
10% owner -
Bioventures Ltd Novartis Ag...,
-
Laurie Stelzer,
-
Jeffrey W. Albers,
-
Cameron Turtle,
Chief Executive Officer -
Funds Management Llc Fairmo...,
-
Heidy King Jones,
See Remarks -
Scott L Burrows,
Chief Financial Officer -
James Wooldridge,
Chief Medical Officer -
Linda L Neuman,
Chief Medical Officer -
Alison Frances Lawton,
Director -
Marcio Souza,
Director -
Steven Weber,
VP, Controller&Princ Acctg Off -
Bros. Advisors Lp667, L.P.B...,
-
Hunter C Smith,
Director -
James Paul Kastenmayer,
General Counsel -
Jeff Marc Goldberg,
President and CEO -
Jonathan Alspaugh,
President and CFO